Kanno Hiroaki, Ishida Kyoko, Yamada Wataru, Nishida Takashi, Takahashi Nobumichi, Mochizuki Kiyofumi, Mizuno Yuki, Matsuyama Kanako, Takahashi Tomoko, Seishima Mariko
Department of Ophthalmology, Gifu University Graduate School of Medicine, Gifu, Japan.
Department of Ophthalmology, Gifu University Graduate School of Medicine, Gifu, Japan; Department of Ophthalmology, Toho University Ohashi Medical Center, Tokyo, Japan.
J Infect Chemother. 2017 Nov;23(11):774-777. doi: 10.1016/j.jiac.2017.04.007. Epub 2017 May 18.
Nivolumab, a new immune checkpoint inhibitor, binds to programmed cell death-protein 1 receptors on T cell, blockades binding of its ligands, and augments the immunologic reaction against tumor cells. Augmented immune response, however, may lead to immune-related adverse events. Herein we describe a rare case of bilateral anterior uveitis induced by nivolumab treatment for metastatic melanoma. A 54-year-old woman presented with mild conjunctival redness and blurred vision two months after initiating nivolumab treatment. Ophthalmological examination revealed bilateral non-granulomatous anterior uveitis. The flare values in the anterior chamber were monitored as an objective inflammatory index during nivolumab therapy and clinical time course was reported in this paper.
纳武单抗是一种新型免疫检查点抑制剂，它与T细胞上的程序性细胞死亡蛋白1受体结合，阻断其配体的结合，并增强针对肿瘤细胞的免疫反应。然而，增强的免疫反应可能会导致免疫相关不良事件。在此，我们描述了一例因纳武单抗治疗转移性黑色素瘤引起双侧前葡萄膜炎的罕见病例。一名54岁女性在开始纳武单抗治疗两个月后出现轻度结膜充血和视力模糊。眼科检查发现双侧非肉芽肿性前葡萄膜炎。在纳武单抗治疗期间，监测前房的闪光值作为客观炎症指标，并报告了临床病程。
